lecture 9 Flashcards

1
Q

crohn’s disease symptoms

A
abdominal pain
diarrhea
nausea
vomiting
weight loss

can affect the entire gastrointestinal tract
has a discontinuous pattern throughout the gastrointestinal tract
(A defect in mucosal innate immunity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ulcerative colitis symptoms

A

abdominal pain
rectal bleeding
bloody diarrhea

affects only the colon
starts at the rectum and progresses continuously through the colon
(A defect in mucosal innate immunity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Revision of mucosal immune mechanisms

A

The surface of the gut is protected by both innate and adaptive immune mechanisms

A layer of mucus made by goblet cells and antimicrobial products produced by Paneth cells help protect against pathogens and keep commensal microorganisms under control

Antigens from food, pathogens and commensals can enter via the M cells and initiate adaptive responses including IgA production

In the absence of infection (inflammation) food and commensal organisms tend to generate a Treg response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In the absence of infection

A

Epithelial layers are the outermost layer - nearest to gut, close association to food and digestive enzymes
We have protective mechanisms for the gut and epithelial layers
Physical barriers are the mucosal layers, form a biofilm to trap foreign molecules
Enterocytes are epithelial cells - recognise infection
Goblet cells - specialised, produce mucus
? antibacterial peptides
Regulatory dampening down of the immune response. We have IgA released to make sure it neutralises the effect of the bacteria
We have dispersed peyer’s patches, role in immunosurveillance (check what is entering our immune system)

DIAGRAM IN L9 S3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

in the presence of infection

A

Professional AG presenting cells (macrophages and dendritic cells) take up bacteria via phagocytosis and present AG.
V
Naïve T and B cells are activated within the GALT, -
B cells undergo class switching from IgM to IgA leave via the lymphatics, fully differentiate, then ‘home’ back to the lamina propria.
T cells become activated and differentiate, leave the GALT again home back to the lamina propria. The GALT can have CD4 helper cels (TH1, TH2, TH17; Treg and CD8 Tc
V
Depending on the activation signals will result in a specific inflammatory immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

TLRs, NOD1 and NOD2 activate NFkB

A

The epithelial cells play a major role in innate defences through the activity of PRRs, TLRs either on the apical surface or in vesicles which recognise PAMPS

NOD 1 and 2 are also PRRs found in the cytoplasm which recognise peptidoglycans released during infection.

Activation of TLRs or NODs activates the pathway NFkB leading to the generation of proinflammatory molecules via gene transcription

These chemokines and cytokines recruit and activate other innate immune cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

crohn’s disease

  • causative agent
  • modifying factors
  • limital factors
A

causative agents: bacteria, virus and dietary
modifying factors: environmental and genetic
limital factors: lumial bacteria, digestive enzymes and bile acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Crohn’s disease results from a breakdown in normal homeostatic mechanisms that occur in the gut

A

Innate and adaptive immunity normally cooperate to limit inflammation.

Mucus layer
Tight junctions between epithelial cells
Antimicrobial peptides from Paneth cells
Treg production which prevents effector T cell production and promotes IgA antibodies

Impaired homeostatic mechanisms lead to dysregulated TH1 and TH17 responses generating chronic inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what does crohn’s disease affect and what are the symptoms?

A

A regional enteritis which can affect any region of the gastrointestinal tract.

The symptoms are

  • Abdominal pain
  • Diarrhea
  • Vomiting
  • Weight loss

It is characterised as either an autoimmune or an immunodeficiency disease
Susceptibility is due to the interaction of both genetic and environmental components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how to analyse patient with crohn’s disease

A

Barium meal analysis of patient with Crohn’s showing narrowing of the bowel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The genetic component of susceptibility

A

The disease runs in families- siblings of sufferers are 30 times more likely to develop disease than the normal population

Genomic studies have associated the disease with a number of genetic loci- the first of which was NOD2

A frame shift mutation in NOD2 was found associated with the disease.

NOD2 deficiency leads to impaired activation of the NFkB pathway which leads to the impaired secretion of anti bacterial peptides called defensins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Environmental factors associated with Crohn’s

A

The increase in Crohn’s in the industrialised world indicates a clear environmental component

Dietary components are
Positive association with increased consumption of animal protein, milk protein and Omega6:Omega3
Negative association with vegetarian diet

Smoking has a strong positive association

Hormonal contraception (1960’s) is associated with dramatic increase in prevalence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Immunological characteristics

A

Originally thought to be T cell mediated autoimmune disorder.

More recently it is thought that impaired cytokine release by macrophages results in impaired innate immunity and sustained inflammatory response in the colon.

Th17 cells are thought to be important in disease.

Characterised by high levels of TNFα like many other autoimmune diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Current available treatments

A

There is no cure for Crohn’s at the present time, all of the treatments are therefore based on alleviating the symptoms.

Most of the treatments are based on reduction of inflammation
Aminosalicylates
Corticosteroids
Immunosuppressants
Biologics like infliximab, certolizumab, natalizumab

In addition- dietary control and surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Biologics – monoclonal antibodies

A

DIAGRAM IN L9 S18-19

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Infliximab-Remicade

A

A chimeric anti TNFα, which has a high affinity for TNFα but not TNFβ

DIAGRAM IN L9 S20

17
Q

Mode of action of infliximab

A

A chimeric mouse/human anti TNFα monoclonal antibody.

Works by binding to TNFα and was originally thought to act by preventing TNFα binding to its receptor.

Actually causes programmed cell death of TNFα bearing activated T lymphocytes.

Elimination of these inflammatory T cells helps to reduce the symptoms of disease

18
Q

infliximab in crohn’s disease

A

Three phenotypes of disease:

  • Stricturing disease which causes a narrowing of the bowel
  • Penetrating disease which causes abnormal connections of the bowel-fistula
  • Inflammatory disease

Infliximab shown to be effective in closing fistula and maintaining closure in 2/3 of patients.

Infliximab also used to induce and maintain remission in inflammatory Crohn’s- giving remission of 30 weeks in up to 45% of patients.

These treatments reduce the need for steroid treatment to get inflammation under control.

19
Q

Certolizumab- CimziaTM

A

This is a product for both RA and Crohn’s disease which consists of a pegylated Fab’ fragment of a humanised anti-TNFα antibody (CDP870).

The Fab’ retains all the biological specificity.

The pegylation (polyethylene glycol) provides extended half life in the serum to about 2 weeks.

Clinical Trial (PRECisE Program) illustrated that 65% of patients showed a clinical response after just 6 weeks.

Long term trials are still on-going.

Application for the licence was granted in 2008.

This is the first subcutaneous injection for the treatment of Crohn’s Disease and can be used through pregnancy since the drug does not cross the placenta